Get started

Stockstowatch

No News Pop For CYCNNo news on April 9th and no filings either. But CYCN jumped to $3.10 after-hours. The initial pop began during the final hours of the afternoon session with a big volume spike that pushed the stock back above $3 for the first time, to the upside, in a few weeks. A MELAS Phase 2a study is underway. So the market could be waiting for any updated data to shed light on progress. As it stands right now, top-line data is expected in “mid-2021.” There’s also a Phase 2a study on patients who have Alzheimer’s disease with vascular pathology. The company is expected to initiate this in “mid-2021” as well. Does Friday’s aftermarket momentum have anything to do with its current pipeline? We’ll have to see how Monday begins. In the meantime, CYCN could be one of the penny stocks to watch this week. Quote Source: Best Penny Stocks To Buy Right Now? 3 For This Week’s Watch List
NASDAQ:CYCN
by PennyStocks101
WSM Stock 10/04/21 Analysis 4H ChartNYSE:WSM - Trend Analysis - 📑Value: 10/20 📈Growth: 18/20 💰Profitability 16/20 🚀Momentum: 20/20 💸Earnings: 18/20 🖇️Total Score: 82/100 Data: Volume 857M Average Volume (3 months) 1.55M Previous Close $185.31 Open $183.97 Shares Outstanding 76.19M Technicals: ( Simple Moving Average ) 10D SMA $180.95 (+1.25%) 50D SMA $144.80 (+26.53%) 200D SMA $109.46 (+67.38%) Market Cap $14.12B Total Debt $1.53B Cash $1.20B Enterprise Value $14.5B Revenue $6.78B Gross Profit $2.65B Net Income $680.71M EPS Diluted $8.61 Free Cash Flow / Share $14.31
NYSE:WSMLong
by investor_kings
DBX Stock 10/04/21 Analysis 4H Chart- Trend Analysis - 📑Value: 10/20 📈Growth: 18/20 💰Profitability 16/20 🚀Momentum: 8/20 💸Earnings: 16/20 🖇️Total Score: 68/100 Data: Volume 4.10M Average Volume (3 months) 8.32M Previous Close $27.69 Open $27.46 Shares Outstanding 319.67M Technicals: ( Simple Moving Average ) 10D SMA $27.04 (-0.18%) 50D SMA $24.98 (+8.06%) 200D SMA $21.88 (+23.38%) Market Cap $11.16B Total Debt $1.12B Cash $1.12B Enterprise Value $11.15B Revenue $1.01B Gross Profit $1.50B Net Income -$256.30M EPS Diluted -$0.62 Free Cash Flow / Share $1.18
NASDAQ:DBXLong
by investor_kings
MSFT Stock 10/04/21 Analysis 4H ChartNASDAQ:MSFT - Trend Analysis - 📑Value: 10/20 📈Growth: 16/20 💰Profitability: 18/20 🚀Momentum: 18/20 💸Earnings: 18/20 🖇️Total Score: 80/100 Data: Volume 24.32M Average Volume (3 months) 30.38M Previous Close $253.25 Open $253 Shares Outstanding 7.54B Technicals: ( Simple Moving Average ) 10D SMA $241.41 (+5.98%) 50D SMA $237.64 (+7.66%) 200D SMA $218.99 (+16.83%) Market Cap $1.91T Total Debt $82.78B Cash $131.99B Enterprise Value $1.86T Revenue $153.28B Gross Profit $104.77B Net Income $51.31B EPS Diluted $6.71 Free Cash Flow / Share $6.66
NASDAQ:MSFTLong
by investor_kings
FB Stock 10/04/21 Analysis 4H Chart- Trend Analysis - 📑Value: 6/20 📈Growth: 16/20 💰Profitability 20/20 🚀Momentum: 18/20 💸Earnings: 16/20 🖇️Total Score: 76/100 Data: Volume 15.98M Average Volume (3 months) 21.17M Previous Close $313.02 Open $311.52 Shares Outstanding 2.41B Technicals: ( Simple Moving Average ) 10D SMA $297.51 (+5.03%) 50D SMA $274.65 (+13.77%) 200D SMA $266.95 (+17.05%) Market Cap $891.38B Total Debt $11.18B Cash $61.95B Enterprise Value $840.60B Revenue $85.97B Gross Profit $69.28B Net Income $29.15B EPS Diluted $10.09 Free Cash Flow / Share $8.29
NASDAQ:METALong
by investor_kings
NFLX - STOCKS - 05. APR. 2021Welcome to our weekly trade setup ( NFLX )! - 4 HOUR Very bullish market structure. DAILY Bearish fake-out with insane price action afterwards. WEEKLY Expecting more bullish price action. - STOCKS SETUP BUY NFLX ENTRY LEVEL @ 534.71 SL @ 504.00 TP @ Open Max Risk: 0.5% - 1%! (Remember to add a few pips to all levels - different Brokers!) Leave us a comment or like to keep our content for free and alive. Have a great week everyone! ALAN
NASDAQ:NFLXLong
by DACapitalTrading
25
$AMT Announces Pricing of Public Offering of Common StockApplied Molecular Transport Announces Proposed Public Offering of Common Stock AMT announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the proposed offering will be sold by AMT. In addition, AMT expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock in the offering. Applied Molecular Transport Announces Pricing of Public Offering of Common Stock AMT today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $42.00 per share.
A
by AlenCiken
3
$Uxin Entry into a Binding Term Sheet with Potential InvestorsUxin Announces Entry into a Binding Term Sheet with Potential Investors $UXIN, a leading nationwide online used car dealer in China, today announced that it has entered into a binding term sheet with two established Asian funds on April 1, 2021, pursuant to which the potential investors have agreed to negotiate and potentially enter into definitive agreements with the Company for the subscription of senior convertible preferred shares. The potential transaction has an aggregate investment amount of potentially up to US$300 million. The completion of the potential transaction is subject to the parties’ execution of definitive agreements and customary closing conditions to be stipulated therein. finance.yahoo.com
NASDAQ:UXIN
by AlenCiken
$JFIN appear to be rising on news or speculation regarding NFTsShares of $JFIN appear to be rising on news or speculation regarding NFTs. For those of you that don't know, NFTs are digital files such as art, video, audio, and other files stored on blockchain, which is the digital ledger technology that powers cryptocurrencies like Bitcoin. Some NFTs have already sold for millions of dollars. Jiayin appear to be linked to speculation that the company may eventually jump into the NFT space. Jiayin is an online individual loan marketplace that seeks to reach underserved customers in China. However, recent buzz on Twitter has people saying the company could potentially get into the NFT space, although there is no real news pointing to that right now. The hype and potential around NFT is certainly at an all-time high and eerily reminiscent of when cryptocurrencies, which are also powered by blockchain, first gained mass popularity several years ago. I would advise caution on anything related to NFTs. While they certainly have taken off in recent months, we are still in very days where the market for these assets will likely remain extremely volatile for quite some time. www.fool.com
NASDAQ:JFIN
by AlenCiken
Is This Volume Any Indicator Of A New Trend?MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things. In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MRKR
by PennyStocks101
Back In The Channel AgainMNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza inhaled insulin product in pediatric subjects. MannKind also explained that it wants to further the development of product candidates in its pipeline. The company may also use a portion of the proceeds for acquisitions or strategic investments in complementary businesses or technologies. Even with the pullback, analysts seem to remain bullish on the company. SVB Leerink most recently adjusted its price target on the stock. It had previously issued a $3 target but upped it to $5. The firm also carries an Outperform rating on the stock. " Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MNKD
by PennyStocks101
SELB Back In High TrafficSELB is back in the upper area of its high-traffic support/resistance from several times prior. Most recently, it saw this act as support in February. But it wasn't able to sustain the level. Anyway, it's back at this but in this case, the level has acted as a potential resistance (for now). It's gonna be interesting to see what happens next. Selecta seems to have benefited from a bullish outlook discussed by the company in its last corporate update. “We are very pleased by the continued progress of our gene therapy program. In collaboration with AskBio, our lead program in methylmalonic acidemia, is on track to enter the clinic in the second quarter of this year, and we expect initial data by the end of the year,” said Carsten Brunn, Ph.D., president, and chief executive officer of Selecta. “A key objective of 2021 will be to generate human data in our gene therapy programs and to continue to build our extensive pipeline in gene therapies, enzyme therapies–with an expected IND filing by the end of the year in IgA nephropathy–and autoimmune diseases, as we work to deliver on our mission to leverage our pioneering ImmTOR platform to improve the lives of patients and their families.” Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
S
by PennyStocks101
Is OPK Fibbin'?OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March? "Ongoing pressure from an activist investor to offload its BioReference unit has also become a source of speculation. This stemmed from recent M&A action within the diagnostics space earlier this month. Needless to say, the recent action in the stock has continued supporting some analysts’ bullish stances on the company. Most recently, Barrington Research boosted its price target to $8 from $7 and maintained its Outperform rating." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:OPK
by PennyStocks101
$TKAT surged yesterday due to hype in NFT art?The Hong Kong-based online art trading platform rose prompted by increased attention from social media amid frenzy surrounding non-fungible tokens. NFTs are akin to a digital certificate of ownership. Takung provides collectors a way to jointly own Asian and other fine arts including paintings, calligraphies, jewelry, and precious gems, according to its website. The hype in NFT art ranging from sneakers to memes have been in the focus of late and a piece from Beeple — “The First 5000 Days” — commanded price tags of millions of dollars. Tesla Inc TSLA CEO Elon Musk also jumped on the bandwagon and put an NFT song — on NFTs — for sale, which the artist Beeple offered to purchase for $69 million, but later changed his mind. www.benzinga.com
T
by AlenCiken